The Hindu Business Line : Ranbaxy gets USFDA nod for capsules to treat urinary infection

RANBAXY Laboratories Ltd has received approval from the US Food and Drug Administration (USFDA) to manufacture and market Nitrofurantoin Monohydrate/Macrocrystals capsules, 100 mg used for the treatment of urinary infection.

The Ranbaxy formulation is bioequivalent and has the same therapeutic effect as Proctor and Gamble Pharmaceuticals Inc's Macrobid.

The total annual market sales for Nitrofurantoin Monohydrate/Macrocrystals capsules last year were $80 million.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Tata Tea divests control in tea estates in Kerala

Drug pricing issue: Ranbaxy to pay £4.5 m to UK health service

Lakshmi Overseas to expand capacity

Ranbaxy gets USFDA nod for capsules to treat urinary infection

Hero Honda hikes prices

IRMA board begins search for new chief — Conspiracy to capture institute, says Kurien

`Present director would have to go'

Balsara Home, now Dabur India arm

Lord of the Rings producer to set up animation studio in India

Indoco Remedies in pact with Strategic Resources for US foray

Chennai boiler plant to restart operations under new name

SAIL turnover set to cross Rs 30,000 cr

PowerGrid eyes Rs 3,000-cr turnover

Tata Steel production hits all-time high

Hero Honda sales jump 27%

Bajaj sales rise 17.8% in March

GM sales up 35%

Midhani PBT at Rs 8.8 crore